Skip to main content
. Author manuscript; available in PMC: 2014 May 21.
Published in final edited form as: Urology. 2013 Oct 19;82(6):1211–1217. doi: 10.1016/j.urology.2013.06.074

Figure 1.

Figure 1

Risk of surpassing an age-specific cut-point (A), undergoing a prostate biopsy by PSA quartile (B), or being diagnosed with prostate cancer (C) stratified by baseline PSA quartiles (Q1 0–0.4, Q2 0.5–0.69, Q3 0.7–0.9, Q4 > 1.0 ng/mL). PSA, prostate-specific antigen. (Color version available online.)